ClearPoint Neuro, Inc. — Director's Dealing 2026

Jan 13, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ClearPoint Neuro, Inc. (CLPT)
CIK: 0001285550
Period of Report: 2026-01-09

Reporting Person: BURNETT JOSEPH (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-09	Common Stock	M	20000	$2.5	Acquired	31565	Direct
2026-01-09	Common Stock	S	20000	$16.12	Disposed	11565	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-09	Stock Options (right to buy)	$2.5	M	20000	Disposed	2027-11-07	Common Stock (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	217059	Indirect

Footnotes

F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.

F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.88 to $16.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

F4: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017.